1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Haemonetics Corp.

Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services.
Christopher Simon

125 Summer Street
Boston, Massachusetts 02110
Phone: 17818487100


Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Jun 21, 2024 19:50pm

No summary available.

Source:Seeking Alpha
Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device | HAE Stock News
Jun 18, 2024 20:15pm

Haemonetics launches VASCADE MVP XL targeting $2.7B vascular market. FDA approved, first success by Dr. McElderry. Enhanced closure capabilities, full release soon.

Source:Stock Titan
Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device
Jun 18, 2024 20:15pm

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VASCADE MVP XL mid-bore venous closure device. The…

Source:PR Newswire
Haemonetics Banks on Growing Plasma Arm, Innovation
Jun 13, 2024 19:41pm

Haemonetics (NYSE: HAE ) has been gaining from business growth within Plasma, Hospital and Hemostasis Management. Its new launches also aid growth. The stock carries a Zacks Rank #1 (Strong Buy) currently. Haemonetics'' Plasma revenues grew 6% in the fourth quarter of fiscal 2024, driven primarily by disposable volume and software. The collections environment in the United States continued to be favorable, with disposables growing 4% in the quarter and 13% in fiscal 2024. The company is gaining from the newly-completed limited market release of the new Express Plus technology with more than 60,000 real-world collections. Haemonetics is currently initiating the full-market release of the new Express Plus technology in the United States. This technology is fast gaining new customers. The rollout of Persona — the company''s proprietary technology proven to increase yield from 9% to 12% on average — continues to gain momentum, with more than 25 million collections. Advancements in NexLynk DMS (Donor Management System), its bidirectional connectivity software, are improving cycle times, reducing errors and allowing staff to focus on taking care of donors and reducing door-to-door time, a key determinant of donor satisfaction.

Haemonetics'' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
Jun 12, 2024 17:34pm

Analyst upgrades Haemonetics to Buy, believes company can reach high-20% operating margin goal by FY26 through product mix analysis. Price target set at $112. … Full story available on Benzinga.com

Haemonetics stock upgraded by Needham, sees ''high-20%'' operating margin target hitting
Jun 12, 2024 10:00am


Haemonetics upsizes private placement to $600 million
May 23, 2024 22:32pm


Haemonetics prices its senior notes offering
May 23, 2024 10:18am

No summary available.

Source:Seeking Alpha
Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes
May 23, 2024 10:00am

BOSTON, May 23, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified…

Source:PR Newswire
Haemonetics exec sells $147,849 in stock, buys $126,773 worth
May 21, 2024 22:04pm